RARE DISEASE
Giant cell tumor of bone
Giant cell tumor of bone
Giant cell tumor of bone
Synonyms: GCT of bone, Osteoclastoma
Synonyms: GCT of bone, Osteoclastoma
Synonyms: GCT of bone, Osteoclastoma
Drug discovery
1
drug
With orphan designation
Overview
Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm composed of mononuclear stromal cells and osteoclast-like giant cells. Typically arising in the epiphysis of long bones (e.g., distal femur, proximal tibia), it primarily affects skeletally mature individuals aged 20–40 years. While GCTB rarely metastasizes (1–3% to lungs), it causes significant bone destruction and has recurrence rates of 15–50% after treatment. Diagnosis relies on imaging (lytic lesions with "soap bubble" appearance) and histopathology [1][4][6][9].
Burden
Local destruction causes pathological fractures (10–30%) and joint dysfunction [4][6][12]
Recurrence: 25–50% after curettage; 5–15% after wide resection [3][9][16]
Economic/QoL impact: Multiple surgeries common (median 2 procedures); 10-year survival drops to 70% with malignant transformation [8][9][13]
Therapies
Surgical: Curettage with adjuvants (phenol, bone cement) ± preoperative denosumab (RANKL inhibitor) to reduce tumor size [3][8][10]. Wide resection reserved for complex cases (pelvis/spine) or recurrence [8][12]
Medical: Denosumab (FDA-approved) for unresectable/metastatic disease, though associated with rebound recurrence post-treatment [3][13][19]
Adjuncts: Embolization for sacral tumors; radiotherapy limited due to malignant transformation risk [5][8][12]
Categories: rare bone diseases, rare neoplastic diseases
Research Papers
1,863 drug discovery papers related to Giant cell tumor of bone, with 3 first-in-class and 4 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
1,863 drug discovery papers related to Giant cell tumor of bone, with 3 first-in-class and 4 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-10 | Short-term Functional Outcomes of Shoulder Girdle Limb Salvage in Primary Bone Tumors: A 2-year Follow-up Study.
The shoulder girdle, encompassing the proximal humerus, scapula, lateral third of the clavicle, and surrounding soft tissues, is the third most frequent site for bone tumors. The proximal humerus is the most commonly affected area, followed by the scapula and clavicle. Managing malignant or aggressive benign bone tumors in this region is particularly challenging due to the proximity to vital neurovascular structures and the need to maintain both stability and dexterity in the shoulder. While traditional treatment often involved extensive resections, contemporary limb salvage techniques focus on preserving function while ensuring effective tumor control. This prospective study included 18 patients who underwent various limb salvage procedures at the Department of Orthopaedics, Vydehi Institute of Medical Sciences and Research Centre in Bengaluru between 2012 and 2019, with a minimum follow-up of 2 years. Diagnosis and staging were performed using imaging modalities and core needle biopsies, with musculoskeletal tumors staged according to the Enneking System. Functional outcomes were assessed using the Musculoskeletal Tumor Society Rating Scale (MSTS). Surgical techniques varied and included endoprosthetic reconstruction, arthrodesis with fibular grafting and plating, and plate fixation with primary shortening. Among the 18 patients, the majority (61%) had giant cell tumors, followed by aneurysmal bone cysts (17%), chondrosarcoma (11%), and osteosarcoma (11%). Functional outcomes, as measured by the MSTS, showed a 75% satisfactory rate. The study population was composed of 55.56% males and 44.44% females. Key parameters evaluated included pain, functional activity, hand positioning, dexterity, lifting ability, and emotional acceptance. Limb salvage surgery for primary bone tumors of the shoulder girdle offers favorable functional outcomes and represents a viable alternative to amputation. Modern reconstruction techniques, such as endoprosthetic reconstruction and fibular grafting with plating, achieve satisfactory results in both function and appearance. The MSTS scoring system is an effective tool for assessing postoperative functional status, and there is a growing preference for less aggressive surgical techniques that preserve limb function while ensuring tumor control.
2026-07-10 | A Rare Case of Giant Cell tumor of Bone in Distal Tibia.
Giant cell tumors of bone commonly seen in the distal femur, proximal tibia and distal radius and are seen in the age group of 20-40 years with female preponderance. Being close to the joint, the management is formidable, and there are no clinical, radiological or histological parameters to predict chances of recurrence or metastasis. Here, we present a rare case of giant cell tumor of the distal tibia treated successfully with no recurrence at the end of 4 years. A 33-year-old female presented with complaints of pain, swelling and decreased range of motion (ROM) at the left ankle joint for 6 weeks. On examination, we observed swelling and tenderness on left ankle joint with decreased ROM. X-rays and computed tomography revealed a well-defined expansile osteolytic lesion in the distal epiphysio-metaphyseal region of the left tibia without breach in the tibial cortex or ankle joint. Surgery by extensive curettage, adjuvants, cementation and prophylactic fixation was performed. Oral alendronate was started and continued for 24 months after surgery. The patient at 4-year follow-up is doing well, walking without pain, able to squat, having full ROM of the ankle joint with no signs of recurrence.
2026-07-01 | Indication-specific use of Denosumab in Giant Cell Tumour of Bone: A retrospective cohort study.
Giant Cell Tumours of Bone (GCTB) are locally aggressive, benign bone tumours. Denosumab was initially introduced as a neoadjuvant therapy to facilitate curettage but is now also used prior to en-bloc resection, as definitive treatment for unresectable disease, and as long-term treatment for recurrent or metastatic disease. Evidence regarding indication-specific outcomes remains limited. This study evaluated contemporary Denosumab use according to treatment intent, focusing on treatment duration, recurrence patterns, and long-term administration. A retrospective review was conducted of all GCTB patients treated with Denosumab at the Royal Orthopaedic Hospital, Birmingham, between 2010 and 2023. Patients were categorized according to treatment intent: 1) Short-course Neoadjuvant Denosumab (SCND), 2) Long-course Neoadjuvant Denosumab (LCND), 3) Definitive Denosumab for unresectable disease, and 4) Long-term Denosumab following local or distant recurrence. The study included 155 patients. Twenty-eight patients (18%) received SCND for median 15 weeks (IQR 11-20), local recurrence occurring in 13 patients (46%). Fifty-two patients (34%) received LCND for median 22 weeks (IQR 13-54), local recurrence occurring in 6 patients (12%). Forty-two patients (27%) received definitive Denosumab for median 123 weeks (IQR 83-182), while 33 patients (21%) received long-term Denosumab following recurrence for median 123 weeks (IQR 29-247). Dose de-escalation was frequently feasible in patients with sustained disease control, whereas adverse events were primarily associated with prolonged treatment exposure. This study demonstrates that Denosumab is used across several distinct clinical indications in GCTB. High recurrence rates were observed following short-course neoadjuvant treatment prior to curettage, whereas prolonged disease control was frequently achieved in selected patients receiving definitive or long-term Denosumab. A preliminary clinical framework for indication-specific Denosumab use is proposed and warrants prospective validation.
2026-07-10 | Short-term Functional Outcomes of Shoulder Girdle Limb Salvage in Primary Bone Tumors: A 2-year Follow-up Study.
The shoulder girdle, encompassing the proximal humerus, scapula, lateral third of the clavicle, and surrounding soft tissues, is the third most frequent site for bone tumors. The proximal humerus is the most commonly affected area, followed by the scapula and clavicle. Managing malignant or aggressive benign bone tumors in this region is particularly challenging due to the proximity to vital neurovascular structures and the need to maintain both stability and dexterity in the shoulder. While traditional treatment often involved extensive resections, contemporary limb salvage techniques focus on preserving function while ensuring effective tumor control. This prospective study included 18 patients who underwent various limb salvage procedures at the Department of Orthopaedics, Vydehi Institute of Medical Sciences and Research Centre in Bengaluru between 2012 and 2019, with a minimum follow-up of 2 years. Diagnosis and staging were performed using imaging modalities and core needle biopsies, with musculoskeletal tumors staged according to the Enneking System. Functional outcomes were assessed using the Musculoskeletal Tumor Society Rating Scale (MSTS). Surgical techniques varied and included endoprosthetic reconstruction, arthrodesis with fibular grafting and plating, and plate fixation with primary shortening. Among the 18 patients, the majority (61%) had giant cell tumors, followed by aneurysmal bone cysts (17%), chondrosarcoma (11%), and osteosarcoma (11%). Functional outcomes, as measured by the MSTS, showed a 75% satisfactory rate. The study population was composed of 55.56% males and 44.44% females. Key parameters evaluated included pain, functional activity, hand positioning, dexterity, lifting ability, and emotional acceptance. Limb salvage surgery for primary bone tumors of the shoulder girdle offers favorable functional outcomes and represents a viable alternative to amputation. Modern reconstruction techniques, such as endoprosthetic reconstruction and fibular grafting with plating, achieve satisfactory results in both function and appearance. The MSTS scoring system is an effective tool for assessing postoperative functional status, and there is a growing preference for less aggressive surgical techniques that preserve limb function while ensuring tumor control.
2026-07-10 | A Rare Case of Giant Cell tumor of Bone in Distal Tibia.
Giant cell tumors of bone commonly seen in the distal femur, proximal tibia and distal radius and are seen in the age group of 20-40 years with female preponderance. Being close to the joint, the management is formidable, and there are no clinical, radiological or histological parameters to predict chances of recurrence or metastasis. Here, we present a rare case of giant cell tumor of the distal tibia treated successfully with no recurrence at the end of 4 years. A 33-year-old female presented with complaints of pain, swelling and decreased range of motion (ROM) at the left ankle joint for 6 weeks. On examination, we observed swelling and tenderness on left ankle joint with decreased ROM. X-rays and computed tomography revealed a well-defined expansile osteolytic lesion in the distal epiphysio-metaphyseal region of the left tibia without breach in the tibial cortex or ankle joint. Surgery by extensive curettage, adjuvants, cementation and prophylactic fixation was performed. Oral alendronate was started and continued for 24 months after surgery. The patient at 4-year follow-up is doing well, walking without pain, able to squat, having full ROM of the ankle joint with no signs of recurrence.
2026-07-01 | Indication-specific use of Denosumab in Giant Cell Tumour of Bone: A retrospective cohort study.
Giant Cell Tumours of Bone (GCTB) are locally aggressive, benign bone tumours. Denosumab was initially introduced as a neoadjuvant therapy to facilitate curettage but is now also used prior to en-bloc resection, as definitive treatment for unresectable disease, and as long-term treatment for recurrent or metastatic disease. Evidence regarding indication-specific outcomes remains limited. This study evaluated contemporary Denosumab use according to treatment intent, focusing on treatment duration, recurrence patterns, and long-term administration. A retrospective review was conducted of all GCTB patients treated with Denosumab at the Royal Orthopaedic Hospital, Birmingham, between 2010 and 2023. Patients were categorized according to treatment intent: 1) Short-course Neoadjuvant Denosumab (SCND), 2) Long-course Neoadjuvant Denosumab (LCND), 3) Definitive Denosumab for unresectable disease, and 4) Long-term Denosumab following local or distant recurrence. The study included 155 patients. Twenty-eight patients (18%) received SCND for median 15 weeks (IQR 11-20), local recurrence occurring in 13 patients (46%). Fifty-two patients (34%) received LCND for median 22 weeks (IQR 13-54), local recurrence occurring in 6 patients (12%). Forty-two patients (27%) received definitive Denosumab for median 123 weeks (IQR 83-182), while 33 patients (21%) received long-term Denosumab following recurrence for median 123 weeks (IQR 29-247). Dose de-escalation was frequently feasible in patients with sustained disease control, whereas adverse events were primarily associated with prolonged treatment exposure. This study demonstrates that Denosumab is used across several distinct clinical indications in GCTB. High recurrence rates were observed following short-course neoadjuvant treatment prior to curettage, whereas prolonged disease control was frequently achieved in selected patients receiving definitive or long-term Denosumab. A preliminary clinical framework for indication-specific Denosumab use is proposed and warrants prospective validation.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Giant cell tumor of bone, including 1 approved therapy.
1 orphan drug designation for Giant cell tumor of bone, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
denosumab [Xgeva] | antibodies | FDA | 2010-12-20 | 2013-06-13 | Amgen, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.